Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

25.67 -0.08 (-0.31%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 14, 2026 Add to My Watchlist

Price and Volume

Volume	1,582,185
Open	25.68
Bid (Size)	25.41 (300)
Ask (Size)	26.80 (1,700)
Prev. Close	25.75
Today's Range	25.36 - 25.95
52wk Range	16.24 - 45.30
Shares Outstanding	308,456,852
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

2 Biotech Stocks Worth Buying Before Their Potential Buyouts ↗

June 27, 2026

It has been a banner year for biotech buyouts, and these are two of the prime targets.

Via The Motley Fool

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

June 23, 2026

Industry Veteran Brings More Than Three Decades of Biopharmaceutical Development and Clinical Operations Experience to Help Guide Pipeline Advancement

From Calidi Biotherapeutics, Inc

Via GlobeNewswire

Performance

YTD	+19.3%	+19.3%
1 Month	-27.6%	-27.6%
3 Month	+45.1%	+45.1%
6 Month	+8.3%	+8.3%
1 Year	-34.9%	-34.9%

More News

Legend Biotech Corporation Announces Pricing of Public Offering

June 17, 2026

From Legend Biotech USA Inc.

Via GlobeNewswire

Legend Biotech (NASDAQ:LEGN) Q1 2026 Revenue Surges on CARVYKTI Growth, but EPS Falls Short ↗

May 12, 2026

Via Chartmill

Legend Biotech Corporation Announces Proposed Public Offering

June 17, 2026

From Legend Biotech USA Inc.

Via GlobeNewswire

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

June 15, 2026

From Legend Biotech USA Inc.

Via GlobeNewswire

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

June 14, 2026

From Legend Biotech USA Inc.

Via GlobeNewswire

Keep an eye on the top gainers and losers in Tuesday's session. ↗

June 02, 2026

Via Chartmill

Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)

June 02, 2026

From Legend Biotech USA Inc.

Via GlobeNewswire

Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026

June 01, 2026

From Legend Biotech USA Inc.

Via GlobeNewswire

Legend Biotech Conference Spotlights CARVYKTI’s Curative Potential, Earlier Use ↗

May 31, 2026

Via MarketBeat

Legend Biotech Announces Presentations at ASCO 2026

May 21, 2026

From Legend Biotech USA Inc.

Via GlobeNewswire

A China Tech Fund Opens a Biotech Position — Here's What That Actually Signals ↗

May 17, 2026

Via The Motley Fool

With YMM Down 29%, First Beijing Bought 13 Million More Shares ↗

May 17, 2026

Via The Motley Fool

Legend Biotech (LEGN) Q1 2026 Earnings Transcript ↗

May 12, 2026

Via The Motley Fool

Legend Biotech Q1 Earnings Call Highlights ↗

May 12, 2026

Via MarketBeat

Legend Biotech Reports First Quarter 2026 Results and Recent Highlights

May 12, 2026

From Legend Biotech USA Inc.

Via GlobeNewswire

Is Yum China a Buy After Investment Firm Matthews Purchased Shares Worth $12.57 Million? ↗

May 05, 2026

Via The Motley Fool

Matthews Just Slashed Its Futu Position -- Here’s Why That Matters ↗

May 04, 2026

Via The Motley Fool

Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth

May 04, 2026

From Legend Biotech USA Inc.

Via GlobeNewswire

Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results

April 28, 2026

From Legend Biotech USA Inc.

Via GlobeNewswire

Why Legend Biotech Stock Crushed the Market on Monday ↗

April 20, 2026

Via The Motley Fool

Legend Biotech (LEGN) Q4 2025 Earnings Transcript ↗

April 01, 2026

Via The Motley Fool

Legend Biotech (LEGN) Q2 2025 Earnings Transcript ↗

April 01, 2026

Via The Motley Fool

Legend Biotech (LEGN) Q4 2024 Earnings Transcript ↗

April 01, 2026

Via The Motley Fool

Frequently Asked Questions

Is Legend Biotech Corporation - American Depositary Shares publicly traded?

Yes, Legend Biotech Corporation - American Depositary Shares is publicly traded.

What exchange does Legend Biotech Corporation - American Depositary Shares trade on?

Legend Biotech Corporation - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Legend Biotech Corporation - American Depositary Shares?

The ticker symbol for Legend Biotech Corporation - American Depositary Shares is LEGN on the Nasdaq Stock Market

What is the current price of Legend Biotech Corporation - American Depositary Shares?

The current price of Legend Biotech Corporation - American Depositary Shares is 25.67

When was Legend Biotech Corporation - American Depositary Shares last traded?

The last trade of Legend Biotech Corporation - American Depositary Shares was at 07/14/26 04:00 PM ET

What is the market capitalization of Legend Biotech Corporation - American Depositary Shares?

The market capitalization of Legend Biotech Corporation - American Depositary Shares is 7.92B

How many shares of Legend Biotech Corporation - American Depositary Shares are outstanding?

Legend Biotech Corporation - American Depositary Shares has 8B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.